Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
AssigneeAclaris Therapeutics, Inc.
InventorsWalter SMITH, Joseph MONAHAN, Edward HELLRIEGEL, David GORDON, Heidi HOPE, John Robert SPRINGER, Gary A. DECRESCENZO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
Claims25
-19. (canceled)
A method for treating cancer, said method comprising:
- administering, to a human subject having cancer, an oral dose of 5 mg/day to 300 mg/day of Compound I
- or a pharmaceutically acceptable salt thereof to treat said cancer;
- wherein Compound I comprises Compound (P)-I and Compound (M)-I;
- wherein Compound (P)-I is crystalline Form A characterized by an PXRD pattern having
- a peak expressed in degrees 2θ at about 9.78±0.2 and wherein said cancer is treated.
A method for treating bone cancer in a human subject in need thereof comprising administering to the human subject an oral dose of 5 mg/day to 300 mg/day of Compound I
- or a pharmaceutically acceptable salt thereof, wherein Compound I comprises crystalline Form A of Compound (P)-I characterized by an PXRD pattern having a peak expressed in degrees 2θ at about 9.78±0.2, wherein the bone cancer in the human subject is treated.
A method for treating breast cancer in a human subject in need thereof comprising administering to the human subject an oral dose of 5 mg/day to 300 mg/day of Compound I
- or a pharmaceutically acceptable salt thereof, wherein Compound I comprises crystalline Form A of Compound (P)-I characterized by an PXRD pattern having a peak expressed in degrees 2θ at about 9.78±0.2, wherein the breast cancer in the human subject is treated.
A method for treating pancreatic cancer in a human subject in need thereof comprising administering to the human subject an oral dose of 5 mg/day to 300 mg/day of Compound I
- or a pharmaceutically acceptable salt thereof, wherein Compound I comprises crystalline Form A of Compound (P)-I characterized by an PXRD pattern having a peak expressed in degrees 2θ at about 9.78±0.2, wherein the pancreatic cancer in the human subject is treated.
Dependencies are inferred from the claim text.